150 results on '"Snyers, An"'
Search Results
2. Optimization of hybrid Directed Energy Deposition through production and microstructure assessment
- Author
-
Jardon, Zoé, Li, Guichuan, Vanmeensel, Kim, Sanchez-Medina, Jorge, Snyers, Charles, Hinderdael, Michaël, Baere, Dieter De, and Pyl, Lincy
- Published
- 2024
- Full Text
- View/download PDF
3. FPGA real-time melt-pool temperature control in Directed Energy Deposition
- Author
-
Sanchez-Medina, Jorge, Jardon, Zoé, Snyers, Charles, Hinderdael, Michaël, Guillaume, Patrick, and Baere, Dieter De
- Published
- 2024
- Full Text
- View/download PDF
4. CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response
- Author
-
Luc Snyers, Sylvia Laffer, Renate Löhnert, Klara Weipoltshammer, and Christian Schöfer
- Subjects
Medicine ,Science - Abstract
Abstract In this study, we characterize the changes in nucleolar morphology and its dynamics induced by the recently introduced compound CX-5461, an inhibitor of ribosome synthesis. Time-lapse imaging, immunofluorescence and ultrastructural analysis revealed that exposure of cells to CX-5461 has a profound impact on their nucleolar morphology and function: nucleoli acquired a compact, spherical shape and display enlarged, ring-like masses of perinucleolar condensed chromatin. Tunnels consisting of chromatin developed as transient structures running through nucleoli. Nucleolar components involved in rRNA transcription, fibrillar centres and dense fibrillar component with their major constituents ribosomal DNA, RNA polymerase I and fibrillarin maintain their topological arrangement but become reduced in number and move towards the nucleolar periphery. Nucleolar changes are paralleled by an increased amount of the DNA damage response indicator γH2AX and DNA unwinding enzyme topoisomerase I in nucleoli and the perinucleolar area suggesting that CX-5461 induces torsional stress and DNA damage in rDNA. This is corroborated by the irreversibility of the observed altered nucleolar phenotypes. We demonstrate that incubation with CX-5461, apart from leading to specific morphological alterations, increases senescence and decreases cell replication. We discuss that these alterations differ from those observed with other drugs interfering with nucleolar functions.
- Published
- 2022
- Full Text
- View/download PDF
5. CX-5461 causes nucleolar compaction, alteration of peri- and intranucleolar chromatin arrangement, an increase in both heterochromatin and DNA damage response
- Author
-
Snyers, Luc, Laffer, Sylvia, Löhnert, Renate, Weipoltshammer, Klara, and Schöfer, Christian
- Published
- 2022
- Full Text
- View/download PDF
6. Combining data to perform population-based observational studies: know your sources. The case of thyroid cancer in Belgium
- Author
-
Decallonne, Brigitte, Snyers, Bérengère, Elaut, Nathalie, Peene, Bernard, Verbeeck, Julie, Van den Bruel, Annick, and De Schutter, Harlinde
- Published
- 2022
- Full Text
- View/download PDF
7. Combining data to perform population-based observational studies: know your sources. The case of thyroid cancer in Belgium
- Author
-
Brigitte Decallonne, Bérengère Snyers, Nathalie Elaut, Bernard Peene, Julie Verbeeck, Annick Van den Bruel, and Harlinde De Schutter
- Subjects
Administrative data sources ,Population-based observational study ,Thyroid cancer ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background Large scale observational studies are crucial to study thyroid cancer incidence and management, known to vary in time and place. Combining cancer registry data with other data sources enables execution of population-based studies, provided data sources are accurate. The objective was to compare thyroid tumour and treatment information between the available data sources in Belgium. Methods We performed a retrospective national population-based cohort study. All patients with thyroid cancer diagnosis in Belgium between 2009 and 2011 (N = 2659 patients) were retrieved from the Belgian Cancer Registry database, containing standard patient and tumour characteristics. Additionally, information was obtained from the following sources: a) detailed pathology reports b) the health insurance company database for reimbursed performed therapeutic acts (both available for N = 2400 patients) c) registration forms for performed and/or planned treatments at the time of the multidisciplinary team meeting (available for N = 1819 patients). More precisely, information was retrieved regarding characteristics of the tumour (histologic subtype, tumour size, lymph node status (source a)) and the treatment (thyroid surgery (a,b,c), lymph node dissection (a,b), postoperative administration of radioactive iodine (b,c)). Results High concordance in histological cancer subtype (> 90%), tumour size (96.2%) and lymph node involvement (89.2%) categories was found between the cancer registry database and the pathology reports. Tumour subcategories (such as microcarcinoma, tumor ≤1 cm diameter) were more specified in the pathology reports. The therapeutic act of thyroid surgery as mentioned in the pathology reports and health insurance company database was concordant in 92.7%, while reports from multidisciplinary team meetings showed 88.5% of concordance with pathology reports and 86.1% with health insurance data. With regard to postoperative radioiodine administration, reports from multidisciplinary teams and health insurance data were concordant in 76.8%. Conclusion Combining registered and/or administrative data results in sufficiently accurate information to perform large scale observational studies on thyroid cancer in Belgium. However, thorough and continuous quality control and insight in strengths and limitations of each cancer data source is crucial.
- Published
- 2022
- Full Text
- View/download PDF
8. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer: Implications for shared decision making
- Author
-
Post, Cathalijne C.B., Mens, Jan Willem M., Haverkort, Marie A.D., Koppe, Friederike, Jürgenliemk-Schulz, Ina M., Snyers, An, Roeloffzen, Ellen M.A., Schaake, Eva E., Slot, Annerie, Stam, Tanja C., Beukema, Jannet C., van den Berg, Hetty A., Lutgens, Ludy C.H.W., Nijman, Hans W., de Kroon, Cornelis D., Kroep, Judith R., Stiggelbout, Anne M., and Creutzberg, Carien L.
- Published
- 2021
- Full Text
- View/download PDF
9. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
- Author
-
McCormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, PJ, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Lutgens, LCHW, Hollema, H, Pras, E, Snyers, A, Westerveld, GH, Jobsen, JJ, Slot, A, Mens, JM, Stam, TC, Van Triest, B, Van der Steen-Banasik, EM, De Winter, KAJ, Quinn, MA, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Colombo, A, Carinelli, S, Ferrero, A, Artioli, G, Davidson, C, McLachlin, CM, Ghatage, P, Rittenberg, PVC, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, Tubiana-Mathieu, N, de Boer, Stephanie M, Powell, Melanie E, Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B, Ledermann, Jonathan A, Khaw, Pearly, D'Amico, Romerai, Fyles, Anthony, Baron, Marie-Helene, Jürgenliemk-Schulz, Ina M, Kitchener, Henry C, Nijman, Hans W, Wilson, Godfrey, Brooks, Susan, Gribaudo, Sergio, Provencher, Diane, Hanzen, Chantal, Kruitwagen, Roy F, Smit, Vincent T H B M, Singh, Naveena, Do, Viet, Lissoni, Andrea, Nout, Remi A, Feeney, Amanda, Verhoeven-Adema, Karen W, Putter, Hein, and Creutzberg, Carien L
- Published
- 2019
- Full Text
- View/download PDF
10. 919: Randomised trial of nurse-led sexual rehabilitation after radiotherapy for gynaecological cancers
- Author
-
Suvaal, Isabelle, Hummel, Lisanne B., Mens, Jan-Willem M., Tuijnman-Raasveld, Charlotte C., Tsonaka, Roula, Velema, Laura A., Westerveld, Henrike, Cnossen, Jeltsje, Snyers, An, Jürgenliemk-Schulz, Ina M., Lutgens, Ludy C.H.W., Beukema, Jannet C., Haverkort, Dorien, Nowee, Marlies E., de Kroon, Cor D., van den Hout, Wilbert B., Creutzberg, Carien L., van Doorn, Lena E., and Kuile, Moniek M. ter
- Published
- 2024
- Full Text
- View/download PDF
11. Comparison and analysis of hyperspectral temperature data in directed energy deposition.
- Author
-
Sanchez-Medina, Jorge, De Baere, Dieter, Snyers, Charles, Jardon, Zoé, Hinderdael, Michaël, Ertveldt, Julien, and Guillaume, Patrick
- Subjects
TEMPERATURE control ,TEMPERATURE ,MANUFACTURING processes ,SPATIAL resolution ,PYROMETERS ,LASER weapons - Abstract
Directed energy deposition is an additive manufacturing process that allows the production of near net shape structures. Moreover, the process can also be applied for the repair of high value components. To obtain structures with consistent good characteristics, the directed energy deposition process requires the implementation of a control system. The currently applied approaches for control that are discussed in the literature have specifically focused on melt-pool temperature control. Pyrometers have been used for such purposes; however, they provide only a single scalar value without any spatial information. In this paper, the implementation of a high-speed hyperspectral camera-based system is discussed with a high spatial resolution unlike the pyrometers. Different calibration and temperature estimation procedures for this camera-based system are evaluated and analyzed. The number of effective wavelengths needed for temperature estimation will be discussed in detail and provide an outlook on the potential of this hyperspectral camera-based system. In addition to the number of wavelengths, another important aspect of the temperature estimation methods is the stability with respect to disturbances. Within this paper, the impact of the nominal laser power will be evaluated on the stability of the temperature signals for a control system. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
12. New taxa, including three new genera show uniqueness of Neotropical Nepticulidae (Lepidoptera)
- Author
-
Erik van Nieukerken, Camiel Doorenweerd, Kenji Nishida, and Chris Snyers
- Subjects
Zoology ,QL1-991 - Abstract
After finding distinct clades in a molecular phylogeny for Nepticulidae that could not be placed in any known genera and discovering clear apomorphic characters that define these clades, as well as a number of Neotropical species that could be placed in known genera but were undescribed, three new genera and nine new species are here described from the Neotropics: Stigmella gallicola van Nieukerken & Nishida, sp. n. reared from galls on Hampea appendiculata (Malvaceae) in Costa Rica, representing the first example of a gall making Stigmella; S. schinivora van Nieukerken, sp. n. reared from leafmines on Schinus terebinthifolia (Anacardiaceae) in Argentina, Misiones; S. costaricensis van Nieukerken & Nishida, sp. n. and S. intronia van Nieukerken & Nishida, sp. n. each from a single specimen collected the same night in Costa Rica, Parque Nacional Chirripó; S. molinensis van Nieukerken & Snyers, sp. n. reared from leafmines on Salix humboldtiana, Peru, Lima, the first Neotropical species of the Stigmella salicis group sensu stricto; Ozadelpha van Nieukerken, gen. n. with type species O. conostegiae van Nieukerken & Nishida, sp. n., reared from leafmines on Conostegia oerstediana (Melastomataceae) from Costa Rica; Neotrifurcula van Nieukerken, gen. n. with type species N. gielisorum van Nieukerken, sp. n. from Chile; Hesperolyra van Nieukerken, gen. n.. with type species Fomoria diskusi Puplesis & Robinson, 2000; Hesperolyra saopaulensis van Nieukerken, sp. n., reared from an unidentified Myrtaceae, Sao Paulo, Brasil; and Acalyptris janzeni van Nieukerken & Nishida, sp. n. from Costa Rica, Guanacaste. Five new combinations are made: Ozadelpha ovata (Puplesis & Robinson, 2000), comb. n. and Ozadelpha guajavae (Puplesis & Diškus, 2002), comb. n., Hesperolyra diskusi (Puplesis & Robinson, 2000), comb. n., Hesperolyra molybditis (Zeller, 1877), comb. n. and Hesperolyra repanda (Puplesis & Diškus, 2002), comb. n. Three specimens are briefly described, but left unnamed: Ozadelpha specimen EvN4680, Neotrifurcula specimen EvN4504 and Neotrifurcula specimen RH2.
- Published
- 2016
- Full Text
- View/download PDF
13. Art. 3:103 WVV
- Author
-
Snyers, Alexander
- Subjects
Law - Published
- 2023
14. Phase II study of definitive chemoradiation for locally advanced squamous cell cancer of the vulva
- Author
-
Ina M. Jürgenliemk-Schulz, Elsbieta M. van der Steen-Banasik, Remi A. Nout, Jannet C. Beukema, Max Peters, Baukelien van Triest, Petronella O. Witteveen, Carien L. Creutzberg, Joanne A. de Hullu, Ludy C.H.W. Lutgens, Jacobus van der Velden, Henrike Westerveld, Marnix J.A. Rasing, An Snyers, Radiotherapy, Obstetrics and Gynaecology, CCA -Cancer Center Amsterdam, CCA - Cancer Treatment and Quality of Life, Targeted Gynaecologic Oncology (TARGON), and Guided Treatment in Optimal Selected Cancer Patients (GUTS)
- Subjects
Adult ,medicine.medical_specialty ,CARCINOMA ,Osteoradionecrosis ,MODULATED RADIATION-THERAPY ,medicine.medical_treatment ,EUROPEAN-ORGANIZATION ,Phases of clinical research ,ORAL FLUOROPYRIMIDINE CARBAMATE ,PREOPERATIVE CHEMORADIATION ,Definitive chemoradiotherapy ,Gastroenterology ,Capecitabine ,All institutes and research themes of the Radboud University Medical Center ,SDG 3 - Good Health and Well-being ,QUALITY-OF-LIFE ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Progression-free survival ,Aged ,Aged, 80 and over ,Salvage Therapy ,Chemotherapy ,Toxicity ,Vulvar cancer ,Vulvar Neoplasms ,business.industry ,Obstetrics and Gynecology ,Chemoradiotherapy ,CHEMOTHERAPY ,Middle Aged ,medicine.disease ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,Radiation therapy ,TOXICITY CRITERIA ,Oncology ,Carcinoma, Squamous Cell ,Locally advanced ,Female ,Organ-sparing ,business ,RADIOTHERAPY ,medicine.drug - Abstract
Objective. To evaluate feasibility of chemoradiation as alternative for extensive surgery in patients with locally advanced vulvar cancer and to report on locoregional control, toxicity and survival. Methods. In a multicenter, prospective phase II trial patients with locally advanced vulvar cancer were treated with locoregional radiotherapy combined with sensitizing chemotherapy (capecitabine). Treatment feasibility, percentage locoregional control, survival and toxicity were evaluated. Results. 52 patients with mainly T2/T3 disease were treated according to the study protocol in 10 centers in the Netherlands from 2007 to 2019. Full dose radiotherapy (tumor dose of 64.8Gy) was delivered in 92% and full dose capecitabine in 69% of patients. Most prevalent acute >_ grade 3 toxicities were regarding skin/ mucosa and pain (54% and 37%). Late >_grade 3 toxicity was reported for skin/mucosa (10%), fibrosis (4%), GI incontinence (4%) and stress fracture or osteoradionecrosis (4%). Twelve weeks after treatment, local clinical complete response (cCR) and regional control (RC) rates were 62% and 75%, respectively. After 2 years, local cCR persisted in 22 patients (42%) and RC was 58%. Thirty patients (58%) had no evidence of disease at end of follow-up (median 35 months). In 9 patients (17%) extensive surgery with stoma formation was needed. Progression free survival was 58%, 51% and 45% and overall survival was 76%, 66%, 52% at 1,2, and 5 years. Conclusions. Definitive capecitabine-based chemoradiation as alternative for extensive surgery is feasible in locally advanced vulvar cancer and results in considerable locoregional control with acceptable survival rates with manageable acute and late toxicity. (c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http:// creativecommons.org/licenses/by-nc-nd/4.0/).
- Published
- 2021
15. Patients' and clinicians' preferences in adjuvant treatment for high-risk endometrial cancer
- Author
-
Cornelis D. de Kroon, Annerie Slot, Jannet C. Beukema, Tanja C. Stam, Judith R. Kroep, Hetty A. van den Berg, Ina M. Jürgenliemk-Schulz, Cathalijne C.B. Post, Jan Willem M. Mens, Ludy C.H.W. Lutgens, F. Koppe, Marie A.D. Haverkort, Ellen M.A. Roeloffzen, An Snyers, Carien L. Creutzberg, Eva E. Schaake, Anne M. Stiggelbout, Hans W. Nijman, Translational Immunology Groningen (TRIGR), Targeted Gynaecologic Oncology (TARGON), Guided Treatment in Optimal Selected Cancer Patients (GUTS), Radiotherapy, Radiotherapie, and RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Survival ,Clinician preferences ,IMPACT ,medicine.medical_treatment ,THERAPY ,VALIDATION ,03 medical and health sciences ,All institutes and research themes of the Radboud University Medical Center ,0302 clinical medicine ,Breast cancer ,Quality of life ,Adjuvants, Immunologic ,Endometrial cancer ,SDG 3 - Good Health and Well-being ,QUALITY-OF-LIFE ,Internal medicine ,Surveys and Questionnaires ,medicine ,Adjuvant therapy ,Humans ,BREAST-CANCER ,SYSTEMIC TREATMENT ,Aged ,Netherlands ,Chemotherapy ,business.industry ,Obstetrics and Gynecology ,Patient preferences ,Chemoradiotherapy ,Middle Aged ,CHEMOTHERAPY ,medicine.disease ,Comorbidity ,Combined Modality Therapy ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,Endometrial Neoplasms ,Adjuvant chemotherapy ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Female ,business ,Adjuvant ,Decision Making, Shared ,Decision-making - Abstract
Background. Decision making regarding adjuvant therapy for high-risk endometrial cancer is complex. The aim of this study was to determine patients' and clinicians' minimally desired survival benefit to choose chemoradiotherapy over radiotherapy alone. Moreover, influencing factors and importance of positive and negative treatment effects (i.e. attribute) were investigated.Methods. Patients with high-risk endometrial cancer treated with adjuvant pelvic radiotherapy with or without chemotherapy and multidisciplinary gynaecologic oncology clinicians completed a trade-off questionnaire based on PORTEC-3 trial data.Results. In total, 171 patients and 63 clinicians completed the questionnaire. Median minimally desired benefit to make chemoradiotherapy worthwhile was significantly higher for patients versus clinicians (10% vs 5%, p = 0.02). Both patients and clinicians rated survival benefit most important during decision making, followed by long-term symptoms. Older patients (OR 0.92 [95%CI 0.87 & ndash;0.97]; p = 0.003) with comorbidity (OR 0.34 [95% CI 0.12 & ndash;0.89]; p = 0.035) had lower preference for chemoradiotherapy, while patients with better numeracy skills (OR 1.2 [95%CI 1.05 & ndash;1.36], p = 0.011) and chemoradiotherapy history (OR 25.0 [95%CI 8.8 & ndash;91.7]; p < 0.001) had higher preference for chemoradiotherapy.& nbsp;Conclusions. There is a considerable difference in minimally desired survival benefit of chemoradiotherapy in high-risk endometrial cancer among and between patients and clinicians. Overall, endometrial cancer patients needed higher benefits than clinicians before preferring chemoradiotherapy.(c) 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
- Published
- 2021
16. Prediction of Melt Pool Temperature for Directed Energy Deposition Using Supervised Learning Methods on Optical Measurement Data
- Author
-
Jan Helsen, Charles Snyers, Julien Ertveldt, Jorge Sanchez Medina, Zoé Jardon, Faculty of Engineering, Engineering Technology, and Applied Mechanics
- Abstract
One of today's ongoing challenges in directed energy deposition (DED) is controlling the geometry and material properties of parts. The objective of this paper is to investigate the relationship between several printing parameters of DED (laser power, laser speed, powder feed rate) and the melt pool temperature. Because DED is a complex and nonlinear process, well-established supervised-learning models such as support vector regression and artificial neural networks are particularly well suited to represent it. The MiCLAD machine, designed at the Vrije Universiteit Brussel, is equipped with a hyperspectral camera that monitors the light emitted at several wavelengths by the melt pool during the building process. A steady-state data set produced by the hyperspectral camera is postprocessed by an advanced temperature estimation method, and the limitations of the temperature estimation method are identified and discussed. The temperature data are used as training data for supervised-learning methods, and a studyis conducted to compare the performance of the considered methods using the measured optical data. This study demonstrates that the melt pool temperature of the DED process can be effectively modeled through the printing parameters thanks to supervised-learning methods.
- Published
- 2022
17. Word-Finding Intervention for Children with Specific Language Impairment: A Multiple Single-Case Study
- Author
-
Bragard, Anne, Schelstraete, Marie-Anne, and Snyers, Perrine
- Abstract
Purpose: This study examined the effectiveness of a combined phonological and semantic intervention for children with specific language impairment who had word-finding difficulties (WFDs). Method: To evaluate the intervention, a multiple single-case design was implemented with 4 children, ages 9;6 (years;months) to 13;9, who had WFDs. Some items were trained using a phonological intervention; others were trained using a semantic one. Lexical access outcomes were measured using a picture-naming test at pre- and posttesting. Results: Three children exhibited a significant reduction in WFDs on the intervention words after 6 sessions. These effects were present at posttest and 6 months later for the treated words only and not the control words. Each child responded differently to the intervention, and these response patterns seemed to be related to each child's linguistic profile. Conclusion: This intervention seemed to achieve long-lasting reductions in children's WFDs. The differential responses to phonological and semantic intervention imply the need to tailor intervention for differing children by matching it to their linguistic profile.
- Published
- 2012
- Full Text
- View/download PDF
18. PORTEC-4a
- Author
-
Nanda Horeweg, Stefan Kommoss, Ludy C.H.W. Lutgens, Katrien Vandecasteele, Marlies E. Nowee, Remi A. Nout, C. Gillham, Bastiaan G Wortman, F. Koppe, Hetty A. van den Berg, Tjalling Bosse, David Cibula, Karen W Verhoeven-Adema, Annerie Slot, Hein Putter, Cyrus Chargari, Ina M. Jürgenliemk-Schulz, Veronique L M A Coen, Aleida G Zwanenburg, Hans W. Nijman, Carien L. Creutzberg, Elzbieta van der Steen-Banasik, Tanja C. Stam, G Henrieke Westerveld, Anne Sophie V M van den Heerik, Wilbert B. van den Hout, Jan Willem M. Mens, An Snyers, Moritz Hamann, Stefan Bijmolt, CCA - Cancer Treatment and Quality of Life, Radiotherapy, Radiotherapie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Targeted Gynaecologic Oncology (TARGON), and Translational Immunology Groningen (TRIGR)
- Subjects
medicine.medical_specialty ,CARCINOMA ,SURGERY ,medicine.medical_treatment ,Brachytherapy ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,SDG 3 - Good Health and Well-being ,law ,Internal medicine ,Medicine and Health Sciences ,medicine ,Clinical endpoint ,Humans ,Multicenter Studies as Topic ,External beam radiotherapy ,Stage (cooking) ,endometrium ,Adverse effect ,Mismatch Repair Endonuclease PMS2 ,Randomized Controlled Trials as Topic ,030304 developmental biology ,0303 health sciences ,business.industry ,Endometrial cancer ,Obstetrics and Gynecology ,radiation oncology ,medicine.disease ,Clinical Trial ,Endometrial Neoplasms ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,DNA-Binding Proteins ,Radiation therapy ,MutS Homolog 2 Protein ,Clinical Trials, Phase III as Topic ,Oncology ,EXTERNAL-BEAM RADIOTHERAPY ,030220 oncology & carcinogenesis ,Female ,Radiotherapy, Adjuvant ,MutL Protein Homolog 1 ,business ,Carcinoma, Endometrioid - Abstract
BackgroundVaginal brachytherapy is currently recommended as adjuvant treatment in patients with high-intermediate risk endometrial cancer to maximize local control and has only mild side effects and no or limited impact on quality of life. However, there is still considerable overtreatment and also some undertreatment, which may be reduced by tailoring adjuvant treatment to the patients’ risk of recurrence based on molecular tumor characteristics.Primary objectivesTo compare the rates of vaginal recurrence in women with high-intermediate risk endometrial cancer, treated after surgery with molecular-integrated risk profile-based recommendations for either observation, vaginal brachytherapy or external pelvic beam radiotherapy or with standard adjuvant vaginal brachytherapyStudy hypothesisAdjuvant treatment based on a molecular-integrated risk profile provides similar local control and recurrence-free survival as current standard adjuvant brachytherapy in patients with high-intermediate risk endometrial cancer, while sparing many patients the morbidity of adjuvant treatment and reducing healthcare costs.Trial designA multicenter, international phase III randomized trial (2:1) of molecular-integrated risk profile-based adjuvant treatment (experimental arm) or adjuvant vaginal brachytherapy (standard arm).Major inclusion/exclusion criteriaWomen aged 18 years and over with a histological diagnosis of high-intermediate risk endometrioid endometrial cancer after total abdominal or laparoscopic hysterectomy and bilateral salpingo-oophorectomy. High-intermediate risk factors are defined as: (i) International Federation of Gynecology and Obstetrics stage IA (with invasion) and grade 3; (ii) stage IB grade 1 or 2 with age ≥60 and/or lymph-vascular space invasion; (iii) stage IB, grade 3 without lymph-vascular space invasion; or (iv) stage II (microscopic and grade 1).EndpointsThe primary endpoint is vaginal recurrence. Secondary endpoints are recurrence-free and overall survival; pelvic and distant recurrence; 5-year vaginal control (including treatment for relapse); adverse events and patient-reported symptoms and quality of life; and endometrial cancer-related healthcare costs.Sample size500 eligible and evaluable patients.Estimated dates for completing accrual and presenting resultsEstimated date for completing accrual will be late 2021. Estimated date for presentation of (first) results is expected in 2023.Trial registrationThe trial is registered at clinicaltrials.gov (NCT03469674) and ISRCTN (11659025).
- Published
- 2020
19. Belgium
- Author
-
Rivière, Inès, Van Goethem, Arvind, and Snyers, Alexander
- Subjects
Law - Abstract
This country report contains a high-level analysis of the Belgian legal system for use by foreign legal practitioners and other interested actors. It is part of the Doing Business in Europe series, an authoritative, easy-to-follow guide to the legal systems of Europe, providing essential legal information for European businesses and their advisers.
- Published
- 2022
20. miRNA expression in anaplastic thyroid carcinomas.
- Author
-
Aline Hébrant, Sébastien Floor, Manuel Saiselet, Aline Antoniou, Alice Desbuleux, Bérengère Snyers, Caroline La, Nicolas de Saint Aubain, Emmanuelle Leteurtre, Guy Andry, and Carine Maenhaut
- Subjects
Medicine ,Science - Abstract
Anaplastic thyroid carcinoma (ATC) is the most lethal form of thyroid neoplasia and represents an end stage of thyroid tumor progression. No effective treatment exists so far. In this study, we analyzed the miRNA expression profiles of 11 ATC by microarrays and their relationship with the mRNA expression profiles of the same 11 ATC samples. ATC show distinct miRNA expression profiles compared to other less aggressive thyroid tumor types. ATC show 18 commonly deregulated miRNA compared to normal thyroid tissue (17 downregulated and 1 upregulated miRNA). First, the analysis of a combined approach of the mRNA gene expression and of the bioinformatically predicted mRNA targets of the deregulated miRNA suggested a role for these regulations in the epithelial to mesenchymal transition (EMT) process in ATC. Second, the direct interaction between one of the upregulated mRNA target, the LOX gene which is an EMT key player, and a downregulated miRNA, the miR-29a, was experimentally validated by a luciferase assay in HEK cell. Third, we confirmed that the ATC tissue is composed of about 50% of tumor associated macrophages (TAM) and suggested, by taking into account our data and published data, their most likely direct or paracrine intercommunication between them and the thyroid tumor cells, amplifying the tumor aggressiveness. Finally, we demonstrated by in situ hybridization a specific thyrocyte localization of 3 of the deregulated miRNA: let-7g, miR-29a and miR-30e and we pointed out the importance of identifying the cell type localization before drawing any conclusion on the physiopathological role of a given gene.
- Published
- 2014
- Full Text
- View/download PDF
21. Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer
- Author
-
Wortman, B.G., Astreinidou, E., Laman, M.S., Steen-Banasik, E.M. van der, Lutgens, L.C.H.W., Westerveld, H., Koppe, F., Slot, A., Berg, H.A. van den, Nowee, M.E., Bijmolt, S., Stam, T.C., Zwanenburg, A.G., Mens, J.W.M., Jurgenliemk-Schulz, I.M., Snyers, A., Gillham, C.M., Weidner, N., Kommoss, S., Vandecasteele, K., Tomancova, V., Creutzberg, C.L., Nout, R.A., PORTEC Study Grp, Radiotherapie, RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Radiotherapy, Targeted Gynaecologic Oncology (TARGON), and CCA - Cancer Treatment and Quality of Life
- Subjects
medicine.medical_specialty ,Dummy run ,CARCINOMA ,IMPACT ,medicine.medical_treatment ,Brachytherapy ,Risk profile ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,0302 clinical medicine ,SDG 3 - Good Health and Well-being ,Endometrial cancer ,RADIATION-THERAPY ,Medicine and Health Sciences ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Medical physics ,DOSE-RATE BRACHYTHERAPY ,Protocol (science) ,OUTCOMES ,business.industry ,Other Research Radboud Institute for Health Sciences [Radboudumc 0] ,Hematology ,medicine.disease ,Checklist ,Quality assurance ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,Endometrial Neoplasms ,Oncology ,Radiology Nuclear Medicine and imaging ,030220 oncology & carcinogenesis ,Vagina ,Female ,Vaginal apex ,business ,Adjuvant ,RADIOTHERAPY - Abstract
Contains fulltext : 229838.pdf (Publisher’s version ) (Open Access) OBJECTIVE: The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachytherapy prior to site activation, and annual quality assurance to verify protocol adherence. Aims of this study were to evaluate vaginal brachytherapy quality and protocol adherence. METHODS: For the dummy run, institutes were invited to create a brachytherapy plan on a provided CT-scan with the applicator in situ. For annual quality assurance, institutes provided data of one randomly selected brachytherapy case. A brachytherapy panel reviewed and scored the brachytherapy plans according to a checklist. RESULTS: At the dummy run, 15 out of 21 (71.4%) institutes needed adjustments of delineation or planning. After adjustments, the mean dose at the vaginal apex (protocol: 100%; 7 Gy) decreased from 100.7% to 99.9% and range and standard deviation (SD) narrowed from 83.6-135.1 to 96.4-101.4 and 8.8 to 1.1, respectively. At annual quality assurance, 22 out of 27 (81.5%) cases had no or minor and 5 out of 27 (18.5%) major deviations. Most deviations were related to delineation, mean dose at the vaginal apex (98.0%, 74.7-114.2, SD 7.6) or reference volume length. CONCLUSIONS: Most feedback during the brachytherapy quality assurance procedure of the PORTEC-4a trial was related to delineation, dose at the vaginal apex and the reference volume length. Annual quality assurance is essential to promote protocol compliance, ensuring high quality vaginal brachytherapy in all participating institutes.
- Published
- 2021
22. Glucocorticoid Up-Regulation of High-Affinity Interleukin 6 Receptors on Human Epithelial Cells
- Author
-
Snyers, L., De Wit, L., and Content, J.
- Published
- 1990
23. Intranasal Analgosedation for Infants in the Neonatal Intensive Care Unit: A Systematic Review.
- Author
-
Snyers, Diane, Tribolet, Sophie, and Rigo, Vincent
- Subjects
- *
NEONATAL intensive care units , *INTRANASAL medication , *INFANTS , *PREMATURE infants , *PAIN management - Abstract
Aim: Pain management is important for newborns' immediate and long-term well-being. While intranasal analgesia and sedation have been well studied in children, their use could be extended to term and preterm infants. This systematic review aims to assess the use of intranasal medications for procedural analgesia or sedation in the neonatal intensive care unit. Methods: MEDLINE via Ovid, Scopus, Embase, and Cochrane Library were searched independently by two reviewers for clinical studies on sedation or analgesia given intranasally. Results: Seven studies, with 401 patients, were included. The studies described various molecules (midazolam, fentanyl, ketamine, or dexmedetomidine) for different procedures such as intubation in the delivery room, screening for retinopathy, or magnetic resonance imaging. All studies reported significant reduction in pain and sedation markers (based on clinical scales, skin conductance, and clinical variables such as heart rate and crying time). Adverse effects were uncommon and mostly consisted in desaturation, apnoea, hypotension, or paradoxical reactions. Discussion and Conclusion: The intranasal route seems a potential alternative for procedural pain management and sedation in neonates, especially when intravenous access is not available. However, data about safety remain limited. Reported sides effects could be attributed to molecules used rather than the intranasal route. Optimal drugs and doses still need to be characterized. Further studies are needed to ensure safety before promoting a widespread use of intranasal medications in neonatology. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
24. Associations between red blood cell and platelet transfusions and retinopathy of prematurity
- Author
-
Hengartner, Tobias, Adams, Mark, Pfister, Riccardo, Snyers, Diane, McDougall, Jane, Waldvogel, Salome, Held-Egli, Katrin, Spring, Lea, Rogdo, Bjarte, Riedel, Thomas, Arlettaz Mieth, Romaine, Swiss Neonatal Network, University of Zurich, and Hengartner, Tobias
- Subjects
medicine.medical_specialty ,congenital, hereditary, and neonatal diseases and abnormalities ,610 Medicine & health ,Red blood cell transfusion ,Logistic regression ,Retinopathy of prematurity ,1309 Developmental Biology ,03 medical and health sciences ,0302 clinical medicine ,030225 pediatrics ,Medicine ,Platelet ,2735 Pediatrics, Perinatology and Child Health ,030212 general & internal medicine ,Prospective cohort study ,Platelet transfusion ,Original Paper ,ddc:618 ,business.industry ,Obstetrics ,Gestational age ,Odds ratio ,10027 Clinic for Neonatology ,medicine.disease ,Confidence interval ,eye diseases ,Pediatrics, Perinatology and Child Health ,business ,Developmental Biology - Abstract
Aim: The aim of this study is to examine possible associations between the transfusion of RBC or platelets (PLTs) and the development of retinopathy of prematurity (ROP) in infants. Methods: This retrospective, national, case-control study included all live births in Switzerland between 2013 and 2018. We investigated preterm infants at a gestational age of n = 178). Each case infant was matched to another of the same sex who did not develop ROP (n = 178, control group). Results: When compared with the control group, we observed higher numbers of RBC transfusions per infant and higher percentages of infants receiving PLT transfusions in the case group. An adjusted logistic regression analysis revealed that both RBC (odds ratio [OR] 1.081, 95% confidence interval [CI] 1.020–1.146) and PLT transfusions (OR = 2.502, 95% CI 1.566–3.998) numbers were associated with ROP development. Conclusions: Multiple RBC and PLT transfusions are associated with higher stage ROP development. Prospective studies are required to determine their potential as risk factors.
- Published
- 2020
25. Belgium
- Author
-
Snyers, Alexander, Van Goethem, Arvind, Rivière, Inès, and Pauwels, Karl
- Subjects
Law - Abstract
This country report contains a high-level analysis of the Belgian legal system for use by foreign legal practitioners and other interested actors. It is part of the Doing Business in Europe series, an authoritative, easy-to-follow guide to the legal systems of Europe, providing essential legal information for European businesses and their advisers.
- Published
- 2020
26. Crypto-assets: key developments, regulatory concerns and responses
- Author
-
Houben, Robby and Snyers, Alexander
- Subjects
Law - Published
- 2020
27. Analgosedation before Less-Invasive Surfactant Administration: A Systematic Review.
- Author
-
Tribolet, Sophie, Hennuy, Nadège, Snyers, Diane, Lefèbvre, Caroline, and Rigo, Vincent
- Subjects
POSITIVE pressure ventilation ,SURFACE active agents ,RESPIRATORY distress syndrome ,PSYCHOLOGICAL distress ,PREMATURE infants ,ARTIFICIAL respiration - Abstract
Background: Surfactant therapy is the cornerstone of respiratory distress syndrome management. "Less-invasive surfactant administration (LISA)" is now recommended for spontaneously breathing preterm infants. Analgosedation remains controversial as 52% of European neonatologists do not use any. This systematic review aims to describe the efficacy and safety of different drugs for analgosedation during LISA. Methods: MEDLINE via Ovid, Embase, Scopus, and Cochrane Library of Trials were searched independently by 2 reviewers for studies on sedation or analgesia for LISA, without filters or limits. Results: Eight studies (1 randomized controlled trial) recruiting 945 infants were included. Infant pain was significantly reduced, with more infants evaluated as comfortable. Failure, defined as need for intubation or for a second dose of surfactant, was not different between sedated and unsedated groups. Analgosedation was associated with a higher occurrence of desaturation and need for positive pressure ventilation during procedure, but the need for mechanical ventilation within 24 or 72 h of life was not significantly different. There does not seem to be any difference in clinical tolerance and complications (e.g., hypotension, mortality, air leaks, etc.). Procedural conditions were evaluated as good or excellent in 83% after sedation. Discussion and Conclusion: Analgesia or sedative drugs increase infant comfort and allow good procedural conditions, with a limited impact on the clinical evolution. Questions remain about the best choice of drugs and dosages, with the constraint to maintain spontaneous breathing and have a rapid offset. Further good quality studies are needed to provide additional evidence to supplement those limited existing data. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
28. Polypoidal choroidal vasculopathy in Caucasians
- Author
-
Lafaut, B. A., Leys, A. M., Snyers, B., Rasquin, F., and De Laey, J. J.
- Published
- 2000
- Full Text
- View/download PDF
29. The assessment of the risk of fracture in femora with metastatic lesions: COMPARING CASE-SPECIFIC FINITE ELEMENT ANALYSES WITH PREDICTIONS BY CLINICAL EXPERTS
- Author
-
Derikx, L. C., van Aken, J. B., Janssen, D., Snyers, A., van der Linden, Y. M., Verdonschot, N., and Tanck, E.
- Published
- 2012
- Full Text
- View/download PDF
30. A Stochastic Heuristic for Visualising Graph Clusters in a Bi-Dimensional Space Prior to Partitioning
- Author
-
Kuntz, Pascale, Snyers, Dominique, and Layzell, Paul
- Published
- 1999
- Full Text
- View/download PDF
31. Cytomegalovirus retinitis after low-dose intravitreous triamcinolone acetonide in an immunocompetent patient: a warning for the widespread use of intravitreous corticosteroids
- Author
-
Vertes, Dora, Snyers, Bernadette, and De Potter, Patrick
- Published
- 2010
- Full Text
- View/download PDF
32. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
- Author
-
de Boer S. M., Powell M. E., Mileshkin L., Katsaros D., Bessette P., Haie-Meder C., Ottevanger P. B., Ledermann J. A., Khaw P., Colombo A., Fyles A., Baron M. -H., Jurgenliemk-Schulz I. M., Kitchener H. C., Nijman H. W., Wilson G., Brooks S., Carinelli S., Provencher D., Hanzen C., Lutgens L. C. H. W., Smit V. T. H. B. M., Singh N., Do V., D'Amico R., Nout R. A., Feeney A., Verhoeven-Adema K. W., Putter H., Creutzberg C. L., McCormack M., Whitmarsh K., Allerton R., Gregory D., Symonds P., Hoskin P. J., Adusumalli M., Anand A., Wade R., Stewart A., Taylor W., Kruitwagen R. F. P. M., Hollema H., Pras E., Snyers A., Stalpers L., Jobsen J. J., Slot A., Mens J. -W. M., Stam T. C., Van Triest B., Van der Steen - Banasik E. M., De Winter K. A. J., Quinn M. A., Kolodziej I., Pyman J., Johnson C., Capp A., Fossati R., Gribaudo S., Lissoni A. A., Ferrero A., Artioli G., Davidson C., McLachlin C. M., Ghatage P., Rittenberg P. V. C., Souhami L., Thomas G., Duvillard P., Berton-Rigaud D., Tubiana-Mathieu N., de Boer, S, Powell, M, Mileshkin, L, Katsaros, D, Bessette, P, Haie-Meder, C, Ottevanger, P, Ledermann, J, Khaw, P, Colombo, A, Fyles, A, Baron, M, Jurgenliemk-Schulz, I, Kitchener, H, Nijman, H, Wilson, G, Brooks, S, Carinelli, S, Provencher, D, Hanzen, C, Lutgens, L, Smit, V, Singh, N, Do, V, D'Amico, R, Nout, R, Feeney, A, Verhoeven-Adema, K, Putter, H, Creutzberg, C, Mccormack, M, Whitmarsh, K, Allerton, R, Gregory, D, Symonds, P, Hoskin, P, Adusumalli, M, Anand, A, Wade, R, Stewart, A, Taylor, W, Kruitwagen, R, Hollema, H, Pras, E, Snyers, A, Stalpers, L, Jobsen, J, Slot, A, Mens, J, Stam, T, Van Triest, B, Van der Steen - Banasik, E, De Winter, K, Quinn, M, Kolodziej, I, Pyman, J, Johnson, C, Capp, A, Fossati, R, Gribaudo, S, Lissoni, A, Ferrero, A, Artioli, G, Davidson, C, Mclachlin, C, Ghatage, P, Rittenberg, P, Souhami, L, Thomas, G, Duvillard, P, Berton-Rigaud, D, and Tubiana-Mathieu, N
- Subjects
Canada ,Antineoplastic Combined Chemotherapy Protocol ,Paclitaxel ,Time Factor ,Risk Factor ,Australia ,Chemoradiotherapy, Adjuvant ,Middle Aged ,Carboplatin ,Europe ,Treatment Outcome ,Gynecologic Surgical Procedures ,Lymph Node Excision ,Endometrial Neoplasm ,Female ,Radiotherapy, Adjuvant ,Dose Fractionation, Radiation ,Cisplatin ,Neoplasm Grading ,Carcinoma, Endometrioid ,Aged ,Human ,Neoplasm Staging ,New Zealand - Abstract
Background: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. Methods: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascular space invasion (or both), endometrioid-type stage II or III, or stage I to III with serous or clear cell histology. Women were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or radiotherapy and chemotherapy (consisting of two cycles of cisplatin 50 mg/m2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2) using a biased-coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The co-primary endpoints were overall survival and failure-free survival. We used the Kaplan-Meier method, log-rank test, and Cox regression analysis for final analysis by intention to treat and adjusted for stratification factors. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is ongoing. PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. Results: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60·2 months (IQR 48·1–73·1). 5-year overall survival was 81·8% (95% CI 77·5–86·2) with chemoradiotherapy versus 76·7% (72·1–81·6) with radiotherapy (adjusted hazard ratio [HR] 0·76, 95% CI 0·54–1·06; p=0·11); 5-year failure-free survival was 75·5% (95% CI 70·3–79·9) versus 68·6% (63·1–73·4; HR 0·71, 95% CI 0·53–0·95; p=0·022). Grade 3 or worse adverse events during treatment occurred in 198 (60%) of 330 who received chemoradiotherapy versus 41 (12%) of 330 patients who received radiotherapy (p
- Published
- 2018
33. Prediction of build geometry for DED using supervised learning methods on simulated process monitoring data.
- Author
-
Snyers, Charles, Ertveldt, Julien, Sanchez-Medina, Jorge, Jardon, Zoé, and Helsen, Jan
- Subjects
THREE-dimensional printing ,FINITE element method ,MACHINE learning ,DEPOSITIONS ,REGRESSION analysis - Abstract
One of today's ongoing challenges in directed energy deposition (DED) is controlling the geometry and material properties of parts. This manufacturing process is complex and nonlinear due to multiple physical phenomena at play and is therefore hard to model analytically. Machine learning (ML) on the contrary is particularly well suited to predict the behavior of a complex process with multiple inputs and outputs such as DED. A significant amount of data is required to train machine learning models, but experimental data are costly time-wise and should therefore be produced in an intelligent way. As a stepping stone for the future production of experimental training data, a finite element model of the process was developed in this study as an unlimited source of training data for the ML models. This model takes into account the printing parameters (laser speed, laser power, and powder flow rate) and outputs' simulated process monitoring data thanks to a postprocessing method that is outlined in this article. A dataset was produced by simulating 102 tracks in 316L stainless steel with the model. From the analysis of this dataset, it was shown that K-nearest neighbors, support vector regression, decision tree regression, linear regression, and artificial neural network models are all capable of modelling the relationship between the printing parameters and the melt pool characteristics effectively. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
34. Brachytherapy quality assurance in the PORTEC-4a trial for high-intermediate risk endometrial cancer
- Author
-
Wortman, B., Astreinidou, E., Laman, M., Lutgens, L., Van der Steen-Banasik, E., Slot, A., Westerveld, H., De Winter, K., Van den Berg, H., Bloemers, M., Stam, T., Mens, J., Zwanenburg, L., Bijmolt, S., Juergenliemk-Schulz, I., Snyers, A., Creutzberg, C., Nout, R., and Targeted Gynaecologic Oncology (TARGON)
- Published
- 2019
35. Choroidal Neovascularization Correlated With Choroidal Ischemia
- Author
-
Guagnini, Ann-Pascale, Snyers, Bernadette, Kozyreff, Alexandra, Levecq, Laurent, and De Potter, Patrick
- Published
- 2006
36. Blau syndrome associated with a CARD15/NOD2 mutation
- Author
-
Snyers, Bernadette and Dahan, Karin
- Subjects
Chromosome abnormalities -- Case studies ,Gene mutations -- Analysis ,Eye -- Abnormalities ,Eye -- Case studies ,Eye -- Genetic aspects ,Health - Published
- 2006
37. Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis
- Author
-
Snyers, Bernadette, Verougstraete, Claire, Postelmans, Laurence, Leys, Anita, and Hykin, Philip
- Published
- 2004
- Full Text
- View/download PDF
38. Fundus changes in membranoproliferative glomerulonephritis type II: A fluorescein angiographic study of 23 patients
- Author
-
Leys, Anita, Vanrenterghem, Yves, Van Damme, Baudewiju, Snyers, Bernadette, Pirson, Yves, and Leys, Monique
- Published
- 1991
- Full Text
- View/download PDF
39. New taxa, including three new genera show uniqueness of Neotropical Nepticulidae (Lepidoptera)
- Author
-
Chris Snyers, Kenji Nishida, Camiel Doorenweerd, Erik J. van Nieukerken, and Staff publications
- Subjects
0106 biological sciences ,Schinus ,Melastomataceae ,010607 zoology ,010603 evolutionary biology ,01 natural sciences ,taxonomy ,lcsh:Zoology ,Botany ,Gall ,Animalia ,lcsh:QL1-991 ,leafmines ,Ecology, Evolution, Behavior and Systematics ,molecular phylogeny ,gall ,biology ,new genus ,Nepticulidae ,biology.organism_classification ,New species ,Lepidoptera ,Type species ,Taxon ,Molecular phylogenetics ,Animal Science and Zoology ,Taxonomy (biology) ,Research Article - Abstract
After finding distinct clades in a molecular phylogeny for Nepticulidae that could not be placed in any known genera and discovering clear apomorphic characters that define these clades, as well as a number of Neotropical species that could be placed in known genera but were undescribed, three new genera and nine new species are here described from the Neotropics: Stigmella gallicola van Nieukerken & Nishida, sp. n. reared from galls on Hampea appendiculata (Malvaceae) in Costa Rica, representing the first example of a gall making Stigmella; S. schinivora van Nieukerken, sp. n. reared from leafmines on Schinus terebinthifolia (Anacardiaceae) in Argentina, Misiones; S. costaricensis van Nieukerken & Nishida, sp. n. and S. intronia van Nieukerken & Nishida, sp. n. each from a single specimen collected the same night in Costa Rica, Parque Nacional Chirripó; S. molinensis van Nieukerken & Snyers, sp. n. reared from leafmines on Salix humboldtiana, Peru, Lima, the first Neotropical species of the Stigmella salicis group sensu stricto; Ozadelpha van Nieukerken, gen. n. with type species O. conostegiae van Nieukerken & Nishida, sp. n., reared from leafmines on Conostegia oerstediana (Melastomataceae) from Costa Rica; Neotrifurcula van Nieukerken, gen. n. with type species N. gielisorum van Nieukerken, sp. n. from Chile; Hesperolyra van Nieukerken, gen. n.. with type species Fomoria diskusi Puplesis & Robinson, 2000; Hesperolyra saopaulensis van Nieukerken, sp. n., reared from an unidentified Myrtaceae, Sao Paulo, Brasil; and Acalyptris janzeni van Nieukerken & Nishida, sp. n. from Costa Rica, Guanacaste. Five new combinations are made: Ozadelpha ovata (Puplesis & Robinson, 2000), comb. n. and Ozadelpha guajavae (Puplesis & Diškus, 2002), comb. n., Hesperolyra diskusi (Puplesis & Robinson, 2000), comb. n., Hesperolyra molybditis (Zeller, 1877), comb. n. and Hesperolyra repanda (Puplesis & Diškus, 2002), comb. n. Three specimens are briefly described, but left unnamed: Ozadelpha specimen EvN4680, Neotrifurcula specimen EvN4504 and Neotrifurcula specimen RH2.
- Published
- 2016
40. Can patient-specific finite element models better predict fractures in metastatic bone disease than experienced clinicians?
- Author
-
Eggermont, F., Derikx, L.C., Verdonschot, N., Geest, I.C.M. van der, Jong, M.A.A. de, Snyers, A., Linden, Y.M. van der, and Tanck, E.
- Subjects
Reconstructive and regenerative medicine Radboud Institute for Health Sciences [Radboudumc 10] ,Metastatic bone disease ,Femur ,Fracture prediction ,Women's cancers Radboud Institute for Health Sciences [Radboudumc 17] ,Finite element modelling - Abstract
Objectives In this prospective cohort study, we investigated whether patient-specific finite element (FE) models can identify patients at risk of a pathological femoral fracture resulting from metastatic bone disease, and compared these FE predictions with clinical assessments by experienced clinicians.Methods A total of 39 patients with non-fractured femoral metastatic lesions who were irradiated for pain were included from three radiotherapy institutes. During follow-up, nine pathological fractures occurred in seven patients. Quantitative CT-based FE models were generated for all patients. Femoral failure load was calculated and compared between the fractured and non-fractured femurs. Due to inter-scanner differences, patients were analyzed separatelyfor the three institutes. In addition, the FE-based predictions were compared with fracture risk assessments by experienced clinicians.Results In institute 1, median failure load was significantly lower for patients who sustained a fracture than for patients with no fractures. In institutes 2 and 3, the number of patients with a fracture was too low to make a clear distinction. Fracture locations were well predicted by the FE model when compared with post-fracture radiographs. The FE model was more accurate in identifying patients with a high fracture risk compared with experienced clinicians, with a sensitivity of 89% versus 0% to 33% for clinical assessments. Specificity was 79% for the FE models versus 84% to 95% for clinical assessments.Conclusion FE models can be a valuable tool to improve clinical fracture risk predictions in metastatic bone disease. Future work in a larger patient population should confirm the higher predictive power of FE models compared with current clinical guidelines.
- Published
- 2018
41. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3) : final results of an international, open-label, multicentre, randomised, phase 3 trial
- Author
-
de Boer, Stephanie M., Powell, Melanie E., Mileshkin, Linda, Katsaros, Dionyssios, Bessette, Paul, Haie-Meder, Christine, Ottevanger, Petronella B., Ledermann, Jonathan A., Khaw, Pearly, Colombo, Alessandro, Fyles, Anthony, Baron, Marie Helene, Jürgenliemk-Schulz, Ina M., Kitchener, Henry C., Nijman, Hans W., Wilson, Godfrey, Brooks, Susan, Carinelli, Silvestro, Provencher, Diane, Hanzen, Chantal, Lutgens, Ludy C.H.W., Smit, Vincent T.H.B.M., Singh, Naveena, Do, Viet, D'Amico, Romerai, Nout, Remi A., Feeney, Amanda, Verhoeven-Adema, Karen W., Putter, Hein, Creutzberg, Carien L., McCormack, Mary, Whitmarsh, Karen, Allerton, Rozenn, Gregory, Deborah, Symonds, Paul, Hoskin, Peter J., Adusumalli, Madhavi, Anand, Anjana, Wade, Robert, Stewart, Alexandra, Taylor, Wendy, Kruitwagen, Roy F.P.M., Hollema, Harry, Pras, Elizabeth, Snyers, An, Stalpers, Lukas, Jobsen, Jan J., Slot, Annerie, Mens, Jan Willem M., and Stam, Tanja C.
- Subjects
Canada ,Time Factors ,Endometrial Neoplasms/mortality ,Clinical Trial, Phase III ,Risk Factors ,Paclitaxel/administration & dosage ,Journal Article ,Humans ,Comparative Study ,Aged ,Neoplasm Staging ,Gynecologic Surgical Procedures/adverse effects ,Antineoplastic Combined Chemotherapy Protocols/adverse effects ,Research Support, Non-U.S. Gov't ,Australia ,Carboplatin/administration & dosage ,Chemoradiotherapy, Adjuvant/adverse effects ,Middle Aged ,Europe ,Multicenter Study ,Treatment Outcome ,Oncology ,Randomized Controlled Trial ,Carcinoma, Endometrioid/mortality ,Lymph Node Excision ,Female ,Radiotherapy, Adjuvant ,Dose Fractionation, Radiation ,Neoplasm Grading ,Cisplatin/administration & dosage ,New Zealand - Abstract
BACKGROUND: Although women with endometrial cancer generally have a favourable prognosis, those with high-risk disease features are at increased risk of recurrence. The PORTEC-3 trial was initiated to investigate the benefit of adjuvant chemotherapy during and after radiotherapy (chemoradiotherapy) versus pelvic radiotherapy alone for women with high-risk endometrial cancer. METHODS: PORTEC-3 was an open-label, international, randomised, phase 3 trial involving 103 centres in six clinical trials collaborating in the Gynaecological Cancer Intergroup. Eligible women had high-risk endometrial cancer with FIGO 2009 stage I, endometrioid-type grade 3 with deep myometrial invasion or lymph-vascular space invasion (or both), endometrioid-type stage II or III, or stage I to III with serous or clear cell histology. Women were randomly assigned (1:1) to receive radiotherapy alone (48·6 Gy in 1·8 Gy fractions given on 5 days per week) or radiotherapy and chemotherapy (consisting of two cycles of cisplatin 50 mg/m 2 given during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m 2) using a biased-coin minimisation procedure with stratification for participating centre, lymphadenectomy, stage of cancer, and histological type. The co-primary endpoints were overall survival and failure-free survival. We used the Kaplan-Meier method, log-rank test, and Cox regression analysis for final analysis by intention to treat and adjusted for stratification factors. The study was closed on Dec 20, 2013, after achieving complete accrual; follow-up is ongoing. PORTEC-3 is registered with ISRCTN, number ISRCTN14387080, and ClinicalTrials.gov, number NCT00411138. RESULTS: 686 women were enrolled between Nov 23, 2006, and Dec 20, 2013. 660 eligible patients were included in the final analysis, of whom 330 were assigned to chemoradiotherapy and 330 were assigned to radiotherapy. Median follow-up was 60·2 months (IQR 48·1-73·1). 5-year overall survival was 81·8% (95% CI 77·5-86·2) with chemoradiotherapy versus 76·7% (72·1-81·6) with radiotherapy (adjusted hazard ratio [HR] 0·76, 95% CI 0·54-1·06; p=0·11); 5-year failure-free survival was 75·5% (95% CI 70·3-79·9) versus 68·6% (63·1-73·4; HR 0·71, 95% CI 0·53-0·95; p=0·022). Grade 3 or worse adverse events during treatment occurred in 198 (60%) of 330 who received chemoradiotherapy versus 41 (12%) of 330 patients who received radiotherapy (p
- Published
- 2018
42. ICOs in Belgium: initial considerations on financial, accounting and tax law implications
- Author
-
Pauwels, Karl and Snyers, Alexander
- Subjects
Law - Published
- 2018
43. ICOs in Belgium : down the rabbit hole into legal no man's land? Part 1
- Author
-
Snyers, Alexander and Pauwels, Karl
- Subjects
Law - Published
- 2018
44. Cryptocurrencies and blockchain : legal context and implications for financial crime, money laundering and tax evasion
- Author
-
Houben, Robby and Snyers, Alexander
- Subjects
Law - Published
- 2018
45. ICOs in Belgium: down the rabbit hole into legal no man's land? Part 2
- Author
-
Pauwels, Karl and Snyers, Alexander
- Subjects
Law - Published
- 2018
46. Recurrent corneal erosion associated with Alport's syndrome: Rapid Communication
- Author
-
Rhys, Ceril, Snyers, Bernadette, and Pirson, Yves
- Published
- 1997
47. PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer.
- Author
-
van den Heerik, Anne Sophie V. M., Horeweg, Nanda, Nout, Remi A., Lutgens, Ludy C. H. W., van der Steen-Banasik, Elzbieta M., Westerveld, G. Henrike, van den Berg, Hetty A., Slot, Annerie, Koppe, Friederike L. A., Kommoss, Stefan, Mens, Jan Willem M., Nowee, Marlies E., Bijmolt, Stefan, Cibula, David, Stam, Tanja C., Jurgenliemk-Schulz, Ina M., Snyers, An, Hamann, Moritz, Zwanenburg, Aleida G., and Coen, Veronique L. M. A.
- Subjects
RANDOMIZED controlled trials ,ENDOMETRIAL cancer ,RADIOISOTOPE brachytherapy ,QUALITY of life ,ADJUVANT treatment of cancer - Abstract
Background Vaginal brachytherapy is currently recommended as adjuvant treatment in patients with highintermediate risk endometrial cancer to maximize local control and has only mild side effects and no or limited impact on quality of life. However, there is still considerable overtreatment and also some undertreatment, which may be reduced by tailoring adjuvant treatment to the patients' risk of recurrence based on molecular tumor characteristics. Primary objectives To compare the rates of vaginal recurrence in women with high-intermediate risk endometrial cancer, treated after surgery with molecularintegrated risk profile-based recommendations for either observation, vaginal brachytherapy or external pelvic beam radiotherapy or with standard adjuvant vaginal brachytherapy Study hypothesis Adjuvant treatment based on a molecular-integrated risk profile provides similar local control and recurrence-free survival as current standard adjuvant brachytherapy in patients with high-intermediate risk endometrial cancer, while sparing many patients the morbidity of adjuvant treatment and reducing healthcare costs. Trial design A multicenter, international phase III randomized trial (2:1) of molecular-integrated risk profilebased adjuvant treatment (experimental arm) or adjuvant vaginal brachytherapy (standard arm). Major inclusion/exclusion criteria Women aged 18 years and over with a histological diagnosis of highintermediate risk endometrioid endometrial cancer after total abdominal or laparoscopic hysterectomy and bilateral salpingo-oophorectomy. High-intermediate risk factors are defined as: (i) International Federation of Gynecology and Obstetrics stage IA (with invasion) and grade 3; (ii) stage IB grade 1 or 2 with age ≥60 and/or lymph-vascular space invasion; (iii) stage IB, grade 3 without lymph-vascular space invasion; or (iv) stage II (microscopic and grade 1). Endpoints The primary endpoint is vaginal recurrence. Secondary endpoints are recurrence-free and overall survival; pelvic and distant recurrence; 5-year vaginal control (including treatment for relapse); adverse events and patient-reported symptoms and quality of life; and endometrial cancer-related healthcare costs. Sample size 500 eligible and evaluable patients. Estimated dates for completing accrual and presenting results Estimated date for completing accrual will be late 2021. Estimated date for presentation of (first) results is expected in 2023. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
48. Three-dimensional architectures grown by simple ‘stigmergic’ agents
- Author
-
Bonabeau, Eric, Guérin, Sylvain, Snyers, Dominique, Kuntz, Pascale, and Theraulaz, Guy
- Published
- 2000
- Full Text
- View/download PDF
49. Cysteine 29 is the major palmitoylation site on stomatin
- Author
-
Snyers, Luc, Umlauf, Ellen, and Prohaska, Rainer
- Published
- 1999
- Full Text
- View/download PDF
50. The assessment of the risk of fracture in femora with metastatic lesions Comparing case-specific finite element analyses with predictions by clinical experts
- Author
-
J.B. van Aken, L.C. Derikx, A. Snyers, Esther Tanck, Y.M. van der Linden, Nicolaas Jacobus Joseph Verdonschot, Dennis Janssen, and Faculty of Engineering Technology
- Subjects
Male ,musculoskeletal diseases ,medicine.medical_specialty ,Metastatic lesions ,Finite Element Analysis ,medicine.disease_cause ,Risk Assessment ,Human Movement & Fatigue Quality of Care [NCEBP 10] ,Weight-bearing ,Quality of Care [ONCOL 4] ,Weight-Bearing ,Bone strength ,Load to failure ,Humans ,Medicine ,Orthopedics and Sports Medicine ,Femur ,METIS-293132 ,Aged ,Aged, 80 and over ,Orthodontics ,Human Movement & Fatigue [NCEBP 10] ,business.industry ,IR-84990 ,Femoral Neoplasms ,Reproducibility of Results ,Middle Aged ,musculoskeletal system ,Finite element method ,Surgery ,Evaluation of complex medical interventions Quality of Care [NCEBP 2] ,Fractures, Spontaneous ,Fracture (geology) ,Female ,Stress, Mechanical ,Fe model ,business ,Femoral Fractures - Abstract
Previously, we showed that case-specific non-linear finite element (FE) models are better at predicting the load to failure of metastatic femora than experienced clinicians. In this study we improved our FE modelling and increased the number of femora and characteristics of the lesions. We retested the robustness of the FE predictions and assessed why clinicians have difficulty in estimating the load to failure of metastatic femora. A total of 20 femora with and without artificial metastases were mechanically loaded until failure. These experiments were simulated using case-specific FE models. Six clinicians ranked the femora on load to failure and reported their ranking strategies. The experimental load to failure for intact and metastatic femora was well predicted by the FE models (R2= 0.90 and R2= 0.93, respectively). Ranking metastatic femora on load to failure was well performed by the FE models (τ = 0.87), but not by the clinicians (0.11 < τ < 0.42). Both the FE models and the clinicians allowed for the characteristics of the lesions, but only the FE models incorporated the initial bone strength, which is essential for accurately predicting the risk of fracture. Accurate prediction of the risk of fracture should be made possible for clinicians by further developing FE models.
- Published
- 2012
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.